Current Liabilities decreased faster than Immutep Limited's Cash & cash equivalent, this led to improvement in Immutep Limited's Quick Ratio to 31.73 a new company high.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Quick Ratio than Immutep Limited in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 166, from total ranking in the third quarter 2025 at 208.

Explain Quick Ratio?
How much Cash & cash equivalents IMMP�s has?
What are IMMP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IMMP/financial-strength

https://api.csimarket.com/api/v1/companies/IMMP/fundamentals

https://api.csimarket.com/api/v1/companies/IMMP/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

IMMP Quick Ratio	(Jun 30 2025) Q4	0 Q3	0 Q2	0 Q1	(Jun 30 2024) Q4
Y / Y Current Liabilities Change	-80.06 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-58.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	31.73	Subscribe	Subscribe	Subscribe	Subscribe
IMMP's Total Ranking	# 166	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-83.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 15
Healthcare Sector	# 25
Overall Market	# 166

Quick Ratio Statistics
High	Average	Low
31.73	8.88	1.31
(Jun 30 2025)		0

Financial Statements
Immutep Limited's Current Liabilities	$ 1 Millions	Visit IMMP's Balance sheet
Immutep Limited's Cash & cash equivalent	$ 44 Millions	Visit IMMP's Balance sheet
Source of IMMP's Sales		Visit IMMP's Sales by Geography

Cumulative Immutep Limited's Quick Ratio

IMMP's Quick Ratio for the trailling 12 Months

IMMP Quick Ratio	(Jun 30 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Jun 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-2.14 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-42.61 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	6.7	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2507	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-12.45 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-19.44 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to IMMP Financial Strength Comparisons >> Go to Compare IMMP Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in IMMP's Current Liabilities to $1.40 millions, cumulative Quick Ratio to 6.7 below the IMMP average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 390 other companies have achieved higher Quick Ratio than Immutep Limited. While Quick Ratio overall ranking has improved so far to 2507, from total ranking during the twelve months ending third quarter 2025 at 2757.

Explain Quick Ratio?
How much Cash & cash equivalents IMMP�s has?
What are IMMP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 391
Healthcare Sector	# 784
Within the Market	# 2507

trailing twelve months Quick Ratio Statistics
High	Average	Low
15.43	9.92	3.13
(Jun 30 2024)		(Jun 30 2019)

Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2025 MRQ Cash & cash equivalent	Jun 30 2025 MRQ Current Liabilities
Bridgebio Oncology Therapeutics Inc	79.56	$ 200.664 Millions	$ 2.522 Millions
Gh Research Plc	73.65	$ 253.873 Millions	$ 3.447 Millions
Benitec Biopharma Inc	67.54	$ 97.799 Millions	$ 1.448 Millions
Structure Therapeutics Inc	53.95	$ 786.500 Millions	$ 14.579 Millions
Disc Medicine Inc	51.95	$ 649.973 Millions	$ 12.511 Millions
Janux Therapeutics Inc	46.59	$ 996.011 Millions	$ 21.379 Millions
Essa Pharma inc	41.85	$ 85.975 Millions	$ 2.054 Millions
Xbiotech Inc	39.65	$ 152.938 Millions	$ 3.857 Millions
Roivant Sciences Ltd	39.55	$ 4,503.151 Millions	$ 113.866 Millions
Apimeds Pharmaceuticals US, Inc.	36.67	$ 8.735 Millions	$ 0.238 Millions
Belite Bio Inc	36.61	$ 352.932 Millions	$ 9.641 Millions
Upstream Bio Inc	36.01	$ 393.581 Millions	$ 10.929 Millions
Bright Minds Biosciences Inc	35.59	$ 63.669 Millions	$ 1.789 Millions
Immutep Limited	31.73	$ 44.307 Millions	$ 1.396 Millions
Protagonist Therapeutics inc	30.59	$ 570.465 Millions	$ 18.646 Millions
Edgewise Therapeutics inc	28.43	$ 593.992 Millions	$ 20.896 Millions
Arca Biopharma Inc	27.12	$ 328.406 Millions	$ 12.110 Millions
Inhibitor Therapeutics Inc	26.70	$ 3.738 Millions	$ 0.140 Millions
Hoth Therapeutics Inc	26.26	$ 9.014 Millions	$ 0.343 Millions
Viking Therapeutics Inc	25.63	$ 807.724 Millions	$ 31.512 Millions
Bicara Therapeutics Inc	25.34	$ 436.606 Millions	$ 17.227 Millions
Monopar Therapeutics Inc	24.94	$ 39.502 Millions	$ 1.584 Millions
Design Therapeutics Inc	24.73	$ 216.276 Millions	$ 8.747 Millions
Terns Pharmaceuticals Inc	24.43	$ 315.445 Millions	$ 12.914 Millions
Contineum Therapeutics Inc	24.33	$ 175.484 Millions	$ 7.214 Millions
Anebulo Pharmaceuticals Inc	23.84	$ 11.628 Millions	$ 0.488 Millions
Fulcrum Therapeutics Inc	23.83	$ 214.111 Millions	$ 8.985 Millions
Trevi Therapeutics Inc	22.77	$ 203.885 Millions	$ 8.955 Millions
Rapport Therapeutics Inc	21.92	$ 260.447 Millions	$ 11.879 Millions
Keros Therapeutics Inc	21.88	$ 690.215 Millions	$ 31.552 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.